Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 9Thoracic 5Breast 5Head & Neck 3Gynecologic 2Genitourinary 2Dermatologic 2Other solid neoplasm 1NET 1Endocrine 1

Conditions

Melanoma 273Carcinoma, Non-Small-Cell Lung 49Carcinoma, Renal Cell 37Uveal Melanoma 23Skin Neoplasms 23Neoplasm Metastasis 23Colorectal Neoplasms 22Carcinoma, Transitional Cell 20Carcinoma, Merkel Cell 20Squamous Cell Carcinoma of Head and Neck 19Neoplasms 18Lung Neoplasms 17Carcinoma, Hepatocellular 16Brain Neoplasms 16Triple Negative Breast Neoplasms 14Uterine Cervical Neoplasms 13Ovarian Neoplasms 13Stomach Neoplasms 12Urinary Bladder Neoplasms 10Small Cell Lung Carcinoma 10Head and Neck Neoplasms 9Lymphoma 8Carcinoma, Basal Cell 8Pancreatic Neoplasms 7Esophageal Neoplasms 7Breast Neoplasms 7Kidney Neoplasms 6Sarcoma 5Prostatic Neoplasms 5Hodgkin Disease 5

Interventions

Radiosurgery 4pazopanib 2atezolizumab 2Nivolumab 2Drug Therapy 2trastuzumab deruxtecan 1pembrolizumab 1osimertinib 1montanide ISA 51 1durvalumab 1cobimetinib 1cemiplimab 1avelumab 1alectinib 1Transurethral Resection of Prostate 1Surveys and Questionnaires 1Specimen Handling 1Sodium Chloride 1Radiotherapy 1Patient-Specific Modeling 1Oncolytic Virotherapy 1Observation 1Nicotine Replacement Therapy 1National Cancer Institute (U.S.) 1Motivational Interviewing 1Microscopy, Electron 1Memantine 1Magnetic Resonance Spectroscopy 1MLN 8237 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × Nivolumab × Dermatologic × Clear all
NCT04336241 2026-02-27

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Replimune, Inc.

Phase 1 Active not recruiting
36 enrolled
BreastDermatologicGastrointestinalThoracic

Uveal Melanoma, Breast Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡